GlassScriptPhysician profile
Hector F Ramirez
NPI 1063663771
$1,929.42
in general payments reported to CMS, 2019-2025
25 companies · $689 in 2025
The $689 reported for 2025 was more than what 86% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $278 · 2020: $114 · 2021: $24.65 · 2022: $61.80 · 2023: $491 · 2024: $272 · 2025: $689.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,451.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,450.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $282.76 | 2019-2024 | Stratafix, Megadyne |
| Hologic Sales and Service, LLC | $233.71 | 2023-2025 | Aptima, Thinprep 2000 Processor, Novasure |
| Mayne Pharma Commercial LLC | $159.57 | 2023-2025 | |
| Meditrina | $148.38 | 2025 | |
| Exeltis, USA INC. | $140.44 | 2022-2025 | Slynd |
| Minerva Surgical, INC | $130.95 | 2019 | |
| Millicent US INC | $118.86 | 2022-2025 | Femlyv, Femring, Intrarosa |
| Medical Device Business Services, INC. | $100.14 | 2020 | |
| Exact Sciences Corporation | $81.47 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $74.69 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $67.20 | 2025 | |
| Sumitomo Pharma America, INC. | $63.28 | 2023 | Myfembree |
| Shield Therapeutics INC | $62.22 | 2024-2025 | |
| Astellas Pharma US INC | $53.44 | 2023 | Veozah, Myrbetriq |
| Organon LLC | $41.36 | 2022-2023 | Nexplanon |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $23.35 | 2025 | Exparel |
| Coopersurgical, INC. | $23.30 | 2025 | Paragard T 380a |
| Agile Therapeutics, INC. | $23.18 | 2023 | Twirla |
| Pfizer INC. | $17.20 | 2025 | |
| Vertical Pharmaceuticals, LLC | $15.28 | 2019 | |
| Gynesonics, INC. | $14.53 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Mimedx Group, INC. | $14.19 | 2024 | |
| Convatec INC. | $13.91 | 2025 | |
| Duchesnay USA Incorporated | $13.37 | 2019 | |
| Myovant Sciences INC. | $12.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$455,331.64 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hector Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.